Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a research note released on Wednesday morning,Benzinga reports. They currently have a $9.00 target price on the stock.

CNTX has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Context Therapeutics in a report on Monday, September 23rd. Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. Finally, JMP Securities began coverage on Context Therapeutics in a research report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $6.33.

Context Therapeutics Stock Up 3.2 %

CNTX opened at $1.01 on Wednesday. Context Therapeutics has a 12-month low of $0.89 and a 12-month high of $2.75. The business has a 50 day moving average of $1.36 and a 200-day moving average of $1.89. The stock has a market cap of $75.75 million, a price-to-earnings ratio of -1.11 and a beta of 2.10.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.11). As a group, analysts expect that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CNTX. Great Point Partners LLC bought a new stake in shares of Context Therapeutics in the second quarter valued at approximately $14,876,000. Blue Owl Capital Holdings LP acquired a new position in Context Therapeutics in the 2nd quarter valued at $10,348,000. Driehaus Capital Management LLC bought a new stake in shares of Context Therapeutics during the 2nd quarter valued at $4,527,000. Nantahala Capital Management LLC acquired a new stake in shares of Context Therapeutics during the 2nd quarter worth $3,881,000. Finally, Franklin Resources Inc. bought a new position in shares of Context Therapeutics in the third quarter worth $3,689,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.